文献速递核素与放射性配体治疗肿瘤 PET/CT

局部晚期宫颈癌影像引导放疗中的淋巴管标测可行性研究

Lymphatic mapping for image-guided radiotherapy in patients with locally advanced uterine cervical cancer: a feasibility study.
PubMed 文献 · EJNMMI Res · 2023-06-12

本研究纳入17例局部晚期宫颈癌患者,在麻醉下注射99mTc-纳米胶体行淋巴管标测联合平面及SPECT/CT显像,评估淋巴管标测识别(微)转移风险淋巴结的可行性及这些淋巴结接受的放疗剂量。结果显示淋巴管标测可行且无并发症,13/17例患者共显示40枚风险淋巴结,其中20/34(58.8%)接受次优放疗,包括7/34未接受放疗、13/34仅接受外照射而未接受同步整合推量。

要点

  • 淋巴管标测在局部晚期宫颈癌中可行,17例患者无并发症发生。
  • 13/17例患者淋巴管标测共显示40枚风险淋巴结,中位每例2枚。
  • 接受放疗的34枚可视淋巴结中20枚(58.8%)放疗次优,7枚未放疗、13枚仅外照射无同步整合推量。

核心结论

  • 淋巴管标测在局部晚期宫颈癌中可行,近60%的风险淋巴结在放化疗中接受次优治疗。
  • 作者认为治疗失败可能由部分淋巴结的(微)转移导致,将风险淋巴结纳入放疗靶区可能改善局部晚期宫颈癌的放疗结局。

研究设计与样本

  • 前瞻性可行性研究,纳入2020年7月至2022年7月间局部晚期宫颈癌患者17例。
  • 纳入标准为≥18岁、拟行根治性放化疗、需在麻醉下进行检查;排除妊娠和极度肥胖。
  • 所有患者行腹部MRI、[18F]FDG-PET/CT及淋巴管标测,注射6-8个99mTc-纳米胶体沉积点后于注射后2-4小时和24小时行平面及SPECT/CT显像。

主要发现

  • 17例患者中13例淋巴管标测共显示40枚风险淋巴结,中位每例2枚(范围0-7,IQR 0.5-3),单侧引流4/13例、双侧引流9/13例。
  • 淋巴管标测显示的淋巴结数多于MRI或[18F]FDG-PET/CT可疑淋巴结的情况见于8/14例患者。
  • 16例患者接受放疗,淋巴管标测可视的34枚淋巴结中20/34(58.8%)接受次优放疗:7/34未接受任何放疗,13/34接受外照射但未接受同步整合推量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymph node metastasis is an important prognostic factor in locally advanced cervical cancer (LACC). No imaging method can successfully detect all (micro)metastases. This may result in (lymph node) recurrence after chemoradiation. We hypothesized that lymphatic mapping could identify nodes at risk and if radiation treatment volumes are adapted based on the lymphatic map, (micro)metastases not shown on imaging could be treated. We investigated the feasibility of lymphatic mapping to image lymph nodes at risk for (micro)metastases in LACC and assessed the radiotherapy dose on the nodes at risk. METHODS: Patients with LACC were included between July 2020 and July 2022. Inclusion criteria were: ≥ 18 years old, intended curative chemoradiotherapy, investigation under anesthesia. Exclusion criteria were: pregnancy and extreme obesity. All patients underwent abdominal MRI, [18F]FDG-PET/CT and lymphatic mapping after administration of 6-8 depots of 99mTc]Tc-nanocolloid followed by planar and SPECT/CT images 2-4 and 24 h post-injection. RESULTS: Seventeen patients participated. In total, 40 nodes at risk were visualized on the lymphatic map in 13/17 patients with a median of two [range 0-7, IQR 0.5-3] nodes per patient, with unilateral drainage in 4/13 and bilateral drainage in 9/13 patients. No complications occurred. The lymphatic map showed more nodes compared to suspicious nodes on MRI or [18F]FDG-PET/CT in 8/14 patients. Sixteen patients were treated with radiotherapy with 34 visualized nodes on the lymphatic map. Of these nodes, 20/34 (58.8%) received suboptimal radiotherapy: 7/34 nodes did not receive radiotherapy at all, and 13/34 received external beam radiotherapy (EBRT), but no simultaneous integrated boost (SIB). CONCLUSION: Lymphatic mapping is feasible in LACC. Almost 60% of nodes at risk received suboptimal treatment during chemoradiation. As treatment failure could be caused by (micro)metastasis in some of these nodes, including nodes at risk in the radiotherapy treatment volume could improve radiotherapy treatment outcome in LACC. Trail registration The study was first registered at the International Clinical Trial Registry Platform (ICTRP) under number of NL9323 on 4 March 2021. Considering the source platform was not operational anymore, the study was retrospectively registered again on February 27, 2023 at CilicalTrials.gov under number of NCT05746156.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Adam JA, Poel E, van Eck-Smit BLF, et al. Lymphatic mapping for image-guided radiotherapy in patients with locally advanced uterine cervical cancer: a feasibility study. EJNMMI Res. 2023. PMID: 37306763. doi:10.1186/s13550-023-00989-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。